Regeneron Pharma

Forecast & Rating27 analysts currently cover Regeneron Pharma, with about 66.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $819.25, about 24.9% upside from the current price of $656.01. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 91.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Regeneron Pharma closely still see room for the stock to rise. Data as of Jul 23, 2026; for reference only and not investment advice.